The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The changes will extend the company's cash runway, enabling it to advance a tri-specific CAR T-cell candidate and its allogeneic cell therapy platform.

A patient found to carry a BRCA1 pathogenic variant is not referred to a certified genetic counselor in her health system.

With permission from a data safety monitoring committee, the firm will begin treating a second cohort with AMT-162 in the EPISOD1 trial in early 2025.